Table 5.
Extreme Phenotype | Dyslipidemia | ||||
---|---|---|---|---|---|
BAD/rs2286615 (C, DOM) | FCRL3/rs2282284 (C,DOM) | BAD (CR) | FCRL3 (CR) | OGFOD3/rs62079523 (C, DOM) | |
OR (95% CI) p-value |
|||||
Age | 1.219 (1.005-1.478) | 1.151 (0.993-1.334) | 1.213 (1.017-1.447) | 1.150 (0.993-1.332) | 1.033 (0.962-1.109) |
0.044 | 0.062 | 0.032 | 0.062 | 0.374 | |
Gender | 1.152 (0.216-6.142) | 1.062 (0.268-4.201) | 1.624 (0.340-7.749) | 1.039 (0.266-4.063) | 0.720 (0.360-1.439) |
0.869 | 0.932 | 0.543 | 0.956 | 0.352 | |
Corticoid | 1.000 (1.000-1.000) | 1.000 (1.000-1.000) | 1.000 (1.000-1.000) | 1.000 (1.000-1.000) | 1.000 (1.000-1.000) |
0.577 | 0.570 | 0.355 | 0.574 | 0.528 | |
Asparaginase | 1.000 (1.000-1.000) | 1.000 (1.000-1.000) | 1.000 (1.000-1.000) | 1.000 (1.000-1.000) | 1.000 (1.000-1.000) |
0.714 | 0.158 | 0.444 | 0.270 | 0.346 | |
Methotrexate | 0.999 (0.999-1.000) | 1.000 (0.999-1.000) | 0.999 (0.999-1.000) | 1.000 (0.999-1.000) | 1.000 (1.000-1.000) |
0.075 | 0.800 | 0.048 | 0.729 | 0.696 | |
CRT | 14.506 (1.116-188.530) | 4.938 (0.687-35.491) | 16.098 (1.220-212.463) | 3.544 (0.561-22.385) | 1.708 (0.668-4.366) |
0.041 | 0.112 | 0.035 | 0.178 | 0.264 | |
Energy balance | 0.999 (0.998-1.001) | 0.999 (0.998-1.000) | 1.000 (0.998-1.001) | 0.999 (0.999-1.000) | 1.000 (0.999-1.000) |
0.297 | 0.304 | 0.421 | 0.306 | 0.210 | |
Med score | 0.652 (0.319-1.329) | 0.884 (0.518-1.509) | 0.752 (0.374-1.513) | 0.815 (0.491-1.353) | 1.008 (0.807-1.259) |
0.239 | 0.651 | 0.425 | 0.430 | 0.944 | |
SNP | 57.900 (3.152-1063.462) | 67.983 (3.393-1362.288) | 68.819 (4.202-1159.995) | 11.695 (1.150-118.907) | 2.712 (1.352-5.442) |
0.006 | 0.006 | 0.003 | 0.038 | 0.005 |
Top: Odds ratio [95% CI], bottom: p-value
Boldface: significant association
C common, CR common/rare, DOM Dominant effect, CRT Cranial radiotherapy, Med score Mediterranean diet score, Extreme phenotype Three and more cardiometabolic risk factor